HomeCompareCTKYY vs JNJ

CTKYY vs JNJ: Dividend Comparison 2026

CTKYY yields 7380.07% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTKYY wins by $2782548293338877.00M in total portfolio value
10 years
CTKYY
CTKYY
● Live price
7380.07%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2782548293338877.00M
Annual income
$2,710,305,372,256,298,600,000.00
Full CTKYY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CTKYY vs JNJ

📍 CTKYY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTKYYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTKYY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTKYY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTKYY
Annual income on $10K today (after 15% tax)
$627,306.27/yr
After 10yr DRIP, annual income (after tax)
$2,303,759,566,417,853,700,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CTKYY beats the other by $2,303,759,566,417,853,700,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTKYY + JNJ for your $10,000?

CTKYY: 50%JNJ: 50%
100% JNJ50/50100% CTKYY
Portfolio after 10yr
$1391274146669438.50M
Annual income
$1,355,152,686,128,149,300,000.00/yr
Blended yield
97.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CTKYY
No analyst data
Altman Z
-1.2
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTKYY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTKYYJNJ
Forward yield7380.07%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$2782548293338877.00M$30.3K
Annual income after 10y$2,710,305,372,256,298,600,000.00$4,689.40
Total dividends collected$2777712434242760.00M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CTKYY vs JNJ ($10,000, DRIP)

YearCTKYY PortfolioCTKYY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$748,707$738,007.38$10,592$272.30+$738.1KCTKYY
2$52,441,451$51,640,333.83$11,289$357.73+$52.43MCTKYY
3$3,436,510,436$3,380,398,083.68$12,123$472.89+$3436.50MCTKYY
4$210,704,089,989$207,027,023,822.12$13,141$629.86+$210704.08MCTKYY
5$12,088,563,443,530$11,863,110,067,242.08$14,408$846.81+$12088563.43MCTKYY
6$649,021,749,235,005$636,086,986,350,428.00$16,021$1,151.60+$649021749.22MCTKYY
7$32,611,102,400,134,300$31,916,649,128,452,844.00$18,122$1,588.22+$32611102400.12MCTKYY
8$1,533,680,270,878,520,000$1,498,786,391,310,376,200.00$20,930$2,228.20+$1533680270878.50MCTKYY
9$67,516,748,675,306,635,000$65,875,710,785,466,630,000.00$24,792$3,191.91+$67516748675306.61MCTKYY
10$2,782,548,293,338,877,000,000$2,710,305,372,256,298,600,000.00$30,274$4,689.40+$2782548293338877.00MCTKYY

CTKYY vs JNJ: Complete Analysis 2026

CTKYYStock

CooTek (Cayman) Inc. operates as a mobile internet company in the United States, the People's Republic of China, and internationally. The company offers Fengdu Novel, a mobile application that provides users with free online novels; and Fengdu Literature, a platform covering 14 major categories of male and female preferred content, including genres of romance, fantasy, science fiction, history, and others. It also provides casual games, such as dress-up games, including Catwalk Beauty, Truth Runner, and Love Fantasy; simulation games comprising Farm Hero and Idle Land King Tycoon; puzzle games, such as Hi Hamster; and educational games consisting of Puzzle No. 1 and Idiom Hero. In addition, the company offers TouchPal Smart Input, an input method for mobile devices that supports approximately 110 languages and available on both Android and iOS operating systems. It distributes its products and acquires users primarily through user downloads from digital distribution platforms and social media. The company was founded in 2008 and is headquartered in Shanghai, the People's Republic of China.

Full CTKYY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CTKYY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTKYY vs SCHDCTKYY vs JEPICTKYY vs OCTKYY vs KOCTKYY vs MAINCTKYY vs ABBVCTKYY vs MRKCTKYY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.